INTRODUCTION
In many patients with inflammatory bowel disease (IBD), the symptoms of abdominal pain, bloating and diarrhoea are out of proportion with the demonstrated degree of inflammation; some symptomatic patients may have complete mucosal healing. Such patients often may undergo invasive, costly and potentially dangerous tests in search of residual inflammation. What are the diagnostic considerations in such patients? How should they be managed?
SYMPTOMS OF IRRITABLE BOWEL SYNDROME IN PATIENTS WITH IBD IN REMISSION
Irritable bowel syndrome (IBS) is a commonly encountered disorder, with point prevalence of w10% 1 ; symptombased criteria facilitate its diagnosis. 2 Although IBD affects w0.4% of the population in the United States and Europe, 3 4 IBD and IBS may concur in a patient, purely by chance. How often do patients with IBD and inflammation in remission manifest symptoms that suggest IBS, usually IBS with diarrhoea (IBS-D)?
From a database of over 1500 patients with IBD, Zaman et al 5 identified 30 with ileal Crohn's disease and 25 with ulcerative colitis involving only the rectosigmoid, and stable symptoms, no changes in medications or use of chronic steroids for 3 months, and no prior bowel surgery. Rome II IBS criteria were met by 67% of patients with Crohn's disease and 60% of ulcerative colitis, with similar symptoms in the two diseases. Thus, symptoms of IBS are common in IBD patients whose inflammation appears to be stable or in remission.
CLINICAL STRATEGY IN SYMPTOMATIC PATIENTS WITH IBD WHO APPEAR TO BE IN REMISSION
In patients who do not suffer IBD, the symptoms of IBS are not sufficiently specific to differentiate, in the absence of objective tests, other conditions such as pelvic floor dyssynergia or coeliac disease that respectively mimic constipationpredominant IBS (IBS-C) and IBS-D. 6 Similarly, in patients with IBD, the presence of diarrhoea, urgency and pain in the absence of significant inflammation typically occur without constitutional symptoms or rectal bleeding, and may result from specific diseases that require specific treatment (figure 1) rather than symptomatic treatment. The first steps are to exclude infection (eg, cytomegalovirus or Clostridium difficile infection), and to confirm that the inflammatory process is sufficiently controlled and unlikely to be the cause of symptoms.
BLOOD AND STOOL TESTS IN DISCRIMINATING IBD FROM IBS
The number of bowel movements, presence of blood in the stool, diverse activity indices, and simple blood tests such as serum C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are used to assess inflammatory activity in IBD. However, activity indices may not necessarily reflect inflammation. In the Crohn's disease activity index (CDAI), abdominal pain, loose stools and general well-being, and the use of diphenoxylate or loperamide for diarrhoea are all manifestations of IBS with diarrhoea and may not reflect inflammation. ESR and CRP are less useful in more subtle IBD; they did not perform as well as stool calprotectin in differentiating 'organic' from 'non-organic' diseases. Table 1 8e15 summarises the ability of other blood and stool markers to discriminate IBD from IBS: faecal calprotectin, lactoferrin and S100A12 (a calcium-binding proinflammatory protein secreted by granulocytes) appear good screening tests to identify residual inflammation.
RADIOLOGICAL IMAGING
When the question of IBS in IBD arises, the patient is symptomatic and colonoscopy has usually excluded active colitis or terminal ileitis. What about small bowel inflammatory disease? Approaches to image the small bowel include barium follow through (or enteroclysis), CT enterography, MR enteroclysis, or capsule endoscopy. 16 Radiolabelled autologous leucocyte scintigraphy is used in few centres.
In general, MR and CTenterography have similar sensitivities for detecting active small bowel inflammation 17 : MR enteroclysis may be preferred because of the absence of radiation exposure and better characterisation of stenotic lesions, whereas CT provides better temporal resolution, mesenteric imaging and shorter length of examination. 18 MR imaging is applied for quantifying IBD severity, though further clinical validation is desirable. 19 
IS DIARRHOEA IN IBD IN REMISSION DUE TO BILE ACID MALABSORPTION?
Hofmann and Poley showed that steatorrhoea occurs when the extent of combined ileal Crohn's disease and resection exceeds 100 cm 20 ; with less than 100 cm of Crohn's disease or resection, diarrhoea results from bile acid malabsorption (BAM). There are three general approaches to diagnose BAM: serum 7a-hydroxy-4-cholesten-3-one (7aC4), an indirect measurement of hepatic bile acid synthesis which is closely related to the faecal loss of bile acids 21 22 ; 48 h faecal bile acid excretion; and 75 Se-HCAT (23-selena-25-homotaurocholate, a synthetic bile acid) retention 23 on scintigraphy, which is based on whole-body retention at 7 days of the radiolabelled bile acid and retention of <12% reflects BAM. A surrogate test is fasting serum fibroblast growth factor (FGF)19, which is reciprocally related to fasting serum 7aC4. 24 Where the tests are not available, therapeutic trials (eg, with cholestyramine 4 g three times a day (tid); oral colesevelam 625 mg tablets, up to two tablets tid) are indicated.
IS THERE ANOTHER CAUSE OF PERSISTENT SYMPTOMS WHEN THE IBD IS IN REMISSION?
must not be multiplied beyond necessity'), and apply a single diagnosis when the symptoms can all fit that diagnosis. However, just as it is possible for patients with paranoid schizophrenia to have real enemies, this principle is not irrefutable.
Symptomatic patients with IBD but without overt inflammation should be further assessed to exclude conditions that are discussed briefly here.
Small bowel bacterial overgrowth and abnormal motility in IBD
Small bowel bacterial overgrowth (SBO) is more likely to occur in Crohn's disease, especially in the presence of strictures, fistulae or by-pass surgery with a blind loop. There is also evidence of impaired propulsive function 25 resulting in stasis and SBO in inactive Crohn's disease.
The diagnosis of SBO is challenging because of poor specificity of the breath hydrogen (H 2 ) excretion tests. 26 For example, in 150 patients with active Crohn's disease, 27 25.3% had positive glucose-H 2 breath test, and these patients reported a higher rate of abdominal complaints, increased stool frequency and lower body weight. There was no correlation with the CDAI; it is unclear why positive tests were more common (26.8%) with exclusive colitis, than with exclusive ileitis (18.8%). Ileocaecal valve resection may be a factor in breath test positivity. 28 Cultures of small bowel aspirates are more specific, but may be less sensitive. Ultimately, a therapeutic trial with a poorly absorbed antibiotic (eg, neomycin, metronidazole, quinolone, rifaximin) may be the most practical clinical approach in suspected SBO.
Coeliac disease
About 1 in 80 of the population has coeliac disease, 29 the incidence being generally proportional to the prevalence of HLA DQ2 or DQ8 haplotypes. Less than 1% have IBD; 3 4 these two relatively rare diseases may occur in the same patient. A database of laboratory tests for coeliac disease and ICD-9 codes for IBD (N¼6908) and coeliac disease (N¼512) over w5 years identified 18 patients with both IBD and coeliac disease. These patients were more often female, commonly had extra-intestinal manifestations and more aggressive disease. 30 Although the concurrence of IBD and coeliac disease appears rare, it is relatively simple to screen for coeliac disease (serum tissue transglutaminase antibodies).
Pancreatic insufficiency
There is 'functional evidence' of pancreatic insufficiency in IBD. In 100 patients with Crohn's disease and 100 patients with ulcerative colitis, and 100 controls, pancreatic insufficiency and its clinical course over 6-month follow-up were tested using faecal elastase-1 (FE-1). FE-1 was #200 mg/g stool in 22 patients with ulcerative colitis and 14 patients with Crohn's disease. However, at 6-month follow-up, FE-1 test was normal in 24/36 patients. Persistently low stool FE-1 was associated with $3 bowel movements per day, loose stools, previous surgery and longer duration of disease, but not with clinically active disease. 31 Rarely, structural idiopathic chronic pancreatitis may occur in IBD. A 16-year experience of three hospitals in France showed eight cases with pancreatic duct stenosis, inter-and intra-lobular fibrosis, or acinar regression in addition to exocrine insufficiency. 32 In that 1999 article, the literature review identified six patients with ulcerative colitis and 14 with Crohn's disease with structural chronic pancreatitis. 32 Painless chronic pancreatitis with exocrine insufficiency and normal or minimally altered pancreatic ducts on endoscopic retrograde cholangiopancreatography (ERCP) is also described. 33 In summary, pancreatic insufficiency should be considered when patients with IBD without significant ileal resection appear to be in remission, and have features suggesting steatorrhoea.
Are pelvic floor dyssynergia and visceral hypersensitivity factors in IBD?
Evacuation disorders are usually confused with IBS-C; 6 however, evacuation disorders may cause urgency and overflow diarrhoea 34 , abdominal or pelvic pain, and bloating, which may mimic IBS-D. Involvement of the rectum and perianal structures, sometimes with fistulation in IBD, may lead to pelvic floor dysfunction (PFD) in patients with IBD. PFD has not been formally assessed in patients with active or inactive IBD. Disorders of ileal pouch evacuation may conceivably cause pouch stasis and predispose to pouchitis. Reduced pouch evacuation is usually attributed to impaired pouch contractility, 35 though PFD has not been investigated. As in non-IBD patients, PFD should be excluded in patients with IBD with abdominal pain, bloating or constipation.
It had been postulated that IBD might predispose to afferent hypersensitivity and, therefore, to the potential for 'IBSlike' symptoms in patients with IBD. However, the data are conflicting, and the main papers in the literature have evaluated sensitivity in pouch patients. Shen sensation of gas, urge to defaecate, and pain sensation ratings at various distension pressures were significantly higher than in pouchitis and normal pouch patients. However, changes in pouch compliance may influence sensation and afferent hypersensitivity may not be the only cause of higher sensation. Similarly, Bernstein et al 37 reported a lower volume threshold for stool sensation in patients with ileal pouches; however, there was also reduced pouch compliance. Conversely, in patients with unoperated ulcerative colitis, discomfort thresholds were higher (suggesting reduced afferent sensitivity) compared with patients with IBS and controls. 38 Increased rectal sensitivity and decreased rectal compliance associated with active ulcerative colitis tended to normalise when colitis went into remission suggesting that inflammation itself does not permanently sensitise afferent nerves to cause hypersensitivity. 39 In summary, there is no convincing evidence for visceral hypersensitivity in patients with unoperated IBD. Further studies of afferent and pelvic floor functions in patients with IBD presenting with symptoms suggestive of IBS are required.
Irritable bowel syndrome: a real association or reflection of occult inflammation?
Some patients with IBD who are in inflammatory remission with persistent abdominal discomfort and diarrhoea may indeed have IBS! Minderhoud et al identified Rome II IBS-like symptoms in patients with IBD in remission in a third of 73 patients with ulcerative colitis and 42% of 34 patients with Crohn's disease who were in remission. The presence of IBS-like symptoms impaired quality of life (QOL). 40 Simren et al documented lower levels of global well-being (PGWB) and QOL and higher levels of anxiety and depression in patients with IBD in remission who have IBS-like symptoms. Anxiety and duration of disease were significant predictors of developing IBSlike symptoms whereas age, use of chronic therapy for IBD or for BAM, and disease extent were not significant risk factors. 41 In a study of patients with IBD in remission (CDAI #150 and UCDAI #3, and serum CRP <10, while off corticosteroids or biologics), IBS-like symptoms were common; however, abnormal faecal calprotectin levels suggest that the mechanism in most cases was occult inflammation rather than coexistent IBS. Faecal calprotectin levels and HAD scores were higher and QOL scores lower in patients with Crohn's disease and those with ulcerative colitis with than in those without IBS-type symptoms. 42 Long and Drossman 43 proposed that peripheral and central factors influence symptom generation in both IBD and IBS. However, it is still unclear what factors determine the presentation of overt inflammatory changes of IBD rather than pauci-inflammatory bowel disturbance of IBS.
CONCLUSION
In patients with IBD in remission in whom residual inflammation or enteral infection are excluded, there may be another disease to which symptoms may be attributed. Effective and relatively inexpensive screening serological tests are available to exclude caeliac disease and BAM. SBO can be suspected based on the anatomical derangements resulting from Crohn's disease or the effects of bypass surgery. There is no easy, sensitive and specific test for SBO, and a therapeutic trial with a poorly absorbed antibiotic may be the most effective approach. Significant chronic pancreatic insufficiency appears to be extremely rare. Ultimately, some patients may have IBS too, and this may be a reflection of a common diathesis for IBD and IBS. In these patients, the IBS can be managed symptomatically. However, it is recommended that anti-motility agents be used judiciously to avoid potential complications of IBD. Measuring gastrointestinal and colonic transit 44 45 may individualise and optimise therapy for the patients with significantly accelerated transit. Sensitivity of 86% and specificity of 96% for distinguishing IBD from IBS Overall accuracy is calculated by addition of the true-positive and true-negative test results. ASCA, anti-Saccharomyces cerevisiae antibodies; CD, Crohn's disease; CRP, C-reactive protein; HCs, healthy controls; OBTI, immunochromatographic test for detection of human haemoglobin; pANCA, perinuclear antineutrophil cytoplasmic antibodies; UC, ulcerative colitis.
